Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer

Video

Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer

CASE:ALK+ Non—Small Cell Lung Cancer

March 2017

  • A 69-year-old female never-smoker presented with dyspnea, cough and fatigue
  • PMH: hypertension managed on losartan 100 mg
  • Chest X-ray showed multiple bilateral lung nodules
  • Brain MRI, negative for intracranial metastases
  • Bronchoscopy was performed with a fine needle aspirate biopsy
    • Pathology revealed adenocarcinoma, consistent with a lung primary tumor
    • Molecular testing:
      • NGS: positive for ALK gene rearrangement
      • NGS: negative forEGFR, ROS1, RET, BRAF, KRAS
      • IHC: PD-L1 expression in 0% of cells
  • The patient was started on therapy with crizotinib
  • Follow-up imaging at 3 and 6 months showed marked regression of the lung mass, nodal spread, and bone lesions

January 2018

  • After 10 months on crizotinib, the patient reported worsening fatigue, back pain, and dyspnea
  • CT showed increased size of the pulmonary masses and bone lesions
  • Brain MRI showed disseminated small lesions
  • Crizotinib was discontinued and the patient was started on brigatinib
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content